Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Basar Bilgicer

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 11, 2020
Engineering peptide-targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacyBaksun Kim, Jaeho Shin, Junmin Wu, et al.
Analytical Chemistry|August 30, 2012
Small-molecule-based affinity chromatography method for antibody purification via nucleotide binding site targetingNathan J Alves, Samuel D Stimple, Michael W Handlogten, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2014
A heterobivalent ligand inhibits mast cell degranulation via selective inhibition of allergen-IgE interactions in vivoMichael W Handlogten, Ana P Serezani, Anthony L Sinn, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 19, 2019
Covalent Heterobivalent Inhibitor Design for Inhibition of IgE-Dependent Penicillin Allergy in a Murine ModelPeter E Deak, Baksun Kim, Byunghee Koh, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 2, 2019
Optimizing design parameters of a peptide targeted liposomal nanoparticle in an in vivo multiple myeloma disease model after initial evaluation in vitroJared F Stefanick, David T Omstead, Jonathan D Ashley, et al.
Molecular Cancer Therapeutics|May 20, 2016
Dual Carfilzomib and Doxorubicin-Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple MyelomaJonathan D Ashley, Charissa J Quinlan, Valerie A Schroeder, et al.
Nanoscale|August 1, 2023
A nanotherapeutic approach to selectively eliminate metastatic breast cancer cells by targeting cell surface GRP78Jaeho Shin, Baksun Kim, Tyson W Lager, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 10, 2019
Cephalosporin Allergy: Current Understanding and Future ChallengesDavid A Khan, Aleena Banerji, Jonathan A Bernstein, et al.
Biomaterials|November 28, 2022
Disease-driven engineering of peptide-targeted DM1 loaded liposomal nanoparticles for enhanced efficacy in treating multiple myeloma by exploring DM1 prodrug chemistrySabrina Khan, Franklin Mejia, Jaeho Shin, et al.
Journal of Hematology & Oncology|November 3, 2020
In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myelomaDavid T Omstead, Franklin Mejia, Jenna Sjoerdsma, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 11, 2020
Engineering peptide-targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacyBaksun Kim, Jaeho Shin, Junmin Wu, et al.
Analytical Chemistry|August 30, 2012
Small-molecule-based affinity chromatography method for antibody purification via nucleotide binding site targetingNathan J Alves, Samuel D Stimple, Michael W Handlogten, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2014
A heterobivalent ligand inhibits mast cell degranulation via selective inhibition of allergen-IgE interactions in vivoMichael W Handlogten, Ana P Serezani, Anthony L Sinn, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 19, 2019
Covalent Heterobivalent Inhibitor Design for Inhibition of IgE-Dependent Penicillin Allergy in a Murine ModelPeter E Deak, Baksun Kim, Byunghee Koh, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 2, 2019
Optimizing design parameters of a peptide targeted liposomal nanoparticle in an in vivo multiple myeloma disease model after initial evaluation in vitroJared F Stefanick, David T Omstead, Jonathan D Ashley, et al.
Molecular Cancer Therapeutics|May 20, 2016
Dual Carfilzomib and Doxorubicin-Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple MyelomaJonathan D Ashley, Charissa J Quinlan, Valerie A Schroeder, et al.
Nanoscale|August 1, 2023
A nanotherapeutic approach to selectively eliminate metastatic breast cancer cells by targeting cell surface GRP78Jaeho Shin, Baksun Kim, Tyson W Lager, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 10, 2019
Cephalosporin Allergy: Current Understanding and Future ChallengesDavid A Khan, Aleena Banerji, Jonathan A Bernstein, et al.
Biomaterials|November 28, 2022
Disease-driven engineering of peptide-targeted DM1 loaded liposomal nanoparticles for enhanced efficacy in treating multiple myeloma by exploring DM1 prodrug chemistrySabrina Khan, Franklin Mejia, Jaeho Shin, et al.
Journal of Hematology & Oncology|November 3, 2020
In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myelomaDavid T Omstead, Franklin Mejia, Jenna Sjoerdsma, et al.
Pageof 6